Our study showed that although SP16 treatment restored the depleted CD4+ T cells, the drug was administered late in NAFLD progression and was therefore unable to fully modulate the hepatic immunological pattern, which appears to be critical in preventing NAFLD-associated HCC. This evidence concerns the gene CD4 and metabolic dysfunction-associated steatotic liver disease.